uniQure NV (LTS:0EE0)
$ 6.32 -0.73 (-10.35%) Market Cap: 312.44 Mil Enterprise Value: -55.20 Mil PE Ratio: 0 PB Ratio: 5.60 GF Score: 73/100

uniQure N.V. - Special Call Transcript

Feb 08, 2019 / 01:30PM GMT
Release Date Price: $30.44
Operator

Thank you for holding for uniQure's investor conference call. Please be advised that this call is being recorded at the company's request and will be archived on the company's website for 2 weeks from today.

At this time, I would like to introduce Mrs. Maria Cantor, uniQure's Senior Vice President of Investor Relations and Communications. Please go ahead.

Maria E. Cantor
uniQure N.V. - SVP of IR & Communication

Good morning, and thank you for joining us as we review updated clinical data from the Phase IIb study of AMT-061 in patients with hemophilia B that were presented earlier today at the EAHAD Medical Conference in Prague.

Joining me on this call are Matt Kapusta, our Chief Executive Officer; Dr. Robert Gut, our Chief Medical Officer; and Dr. Annette von Drygalski, Associate Clinical Professor of Medicine and Director of the Hemophilia and Thrombosis Treatment Center at the University of California in San Diego. Slides from the oral presentations delivered by Dr. von Drygalski at EAHAD are now available through this webcast and can

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot